Market Access Impact (US) [Parkinson's Disease]
Are high cost and market access problems costing your brand market share?
Are market barriers holding your brand back? According to our survey of US-based neurologists, 8 of the 11 Parkinson’s disease treatments we asked them about are losing market share because of barriers. High cost and market access problems are the main culprits, but understanding the unique combination of barriers and competitive dynamics your brand faces is critical if you want to take back enough share to move ahead of rivals.
Learn how 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Parkinson’s Disease (US).
Based on a survey of 100 US-based neurologists, the report covers 11 major therapies from Abbvie, GlaxoSmithKline, Impax Pharmaceuticals, Novartis, Teva, UCB, US Worldmeds, and Valeant.
Reasons to Purchase
Most brands lose share: Barriers affect a quarter of all prescriptions, and all but 3 of the surveyed brands see a net market share loss because of them.
Market access is the #1 challenge: Market access barriers affect more prescriptions than any others.
Many brands are too expensive: 30%-50% of surveyed doctors can’t prescribe 7 of the surveyed brands due to cost.
One brand is having trouble getting onto formularies: More than 40% of doctors can’t prescribe this brand because it’s not included.
Another brand has a huge perception problem: Nearly half of surveyed doctors would not consider prescribing it.
Eliminating barriers would shake up the market: 5 brands would climb by 1 or 2 places each, and 2 of them would close in on the second-place brand.
Insight into 11 Major Parkinson’s disease Drugs
Apokyn (apomorphine; US Worldmeds)
Azilect (rasagiline; Teva)
Comtan (entacapone; Novartis)
Duopa (levodopa/carbidopa intraduodenal; Abbvie)
Neupro (rotigotine; UCB)
Requip (ropinirole; GlaxoSmithKline)
Requip XL (ropinirole ER; GlaxoSmithKline)
Rytary (levodopa/carbidopa; Impax Pharmaceuticals)
Stalevo (levodopa/carbidopa/entacapone; Novartis)
Tasmar (tolcapone; Valeant)
Xadago (safinamide; US Worldmeds)
Paragraph>Exploring Market Access Barriers
Market Access Impact: Parkinson’s Disease (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?
How barriers affect your brand:
How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 100 US-based neurologists, chosen from the largest community of validated physicians in the world.
All respondents have:
Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with Parkinson’s disease in the last month
We conducted the survey between June 1st and 7th, 2017.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook